PHD, Director Business Development, PathAI
Biography
Ruby Hsu earned her BA from Harvard University and her PhD in Neurobiology from Columbia University, before completing postdoctoral studies at the University of California San Francisco. She joined Advanced Cell Diagnostics (now a Bio-Techne company) as an early employee and served as the commercial and operational leader of the CRO business prior to becoming Director of Business Development. She is now Director of Biopharma Partnerships at PathAI, a leader in the development and application of artificial intelligence for computational pathology.
AI and Data Sciences Showcase:
PathAI
At PathAI, we’re dedicated to improving patient outcomes with reliable AI-Powered technology and meaningful collaboration with biopharma, laboratories, and clinicians — aiming to provide patients with access to accurate diagnoses and effective treatments.
AI Powered Pathology in Precision Medicine
PathAI is developing AI-powered digital pathology algorithms for translational and clinical development.
Session Abstract – PMWC 2022 Silicon Valley
Track 7 - June 28 10.00 A.M.-1.15 P.M.,Track 7 - June 29 11.00 A.M.-1.15 P.M.,Track 7 - June 30 9.00 A.M.-11.15 A.M.
The PMWC 2022 AI Company Showcase will provide a 15-minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.
